menu search

Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection

Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent Clostridioides difficile infection in 2024. SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug […] The post Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection... Read More
Posted: Sep 5 2023, 11:59
Author Name: forextv
Views: 111593

Search within

Pages Search Results: